Corbus Pharmaceuticals Holdings, Inc. (CRBP) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 90.26M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 6.73M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -106.88M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $90.26M | (m) | $6.73M | $-106.88M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $74.27M | (m) | $6.49M | $-89.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $70.09M | (m) | $6.29M | $-85.31M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $60.48M | (m) | $6.49M | $-75.95M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $50.42M | (m) | $7.15M | $-67.04M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $42.10M | (m) | $6.88M | $-58.87M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $32.22M | (m) | $6.14M | $-48.72M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $30.41M | (m) | $5.31M | $-46.22M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $26.16M | (m) | $3.89M | $-40.20M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $23.54M | (m) | $3.43M | $-37.40M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $31.17M | (m) | $3.47M | $-45.08M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $30.43M | (m) | $3.94M | $-45.77M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $27.99M | (m) | $4.46M | $-44.46M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $26.24M | (m) | $5.15M | $-48.62M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $16.14M | $0.00 | $5.72M | $-39.84M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $15.66M | $0.00 | $6.24M | $-39.04M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $20.25M | (m) | $7.50M | $-44.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $29.01M | $233.88K | $8.49M | $-49.09M | (m) | 12404.04% | 3630.79% | (m) | (m) |
| 2021-12-31 | $36.45M | $881.71K | $9.48M | $-55.99M | (m) | 4133.50% | 1075.23% | (m) | (m) |
| 2021-09-30 | $46.79M | $1.54M | $10.03M | $-66.80M | (m) | 3038.62% | 651.23% | (m) | (m) |
| 2021-06-30 | $65.62M | $2.67M | $11.06M | $-86.90M | (m) | 2454.70% | 413.74% | (m) | (m) |
| 2021-03-31 | $85.04M | $2.82M | $11.90M | $-108.34M | (m) | 3012.41% | 421.58% | (m) | (m) |
| 2020-12-31 | $98.27M | $3.94M | $12.46M | $-122.81M | (m) | 2495.85% | 316.42% | (m) | (m) |
| 2020-09-30 | $105.64M | $5.85M | $13.21M | $-129.19M | (m) | 1805.11% | 225.79% | (m) | (m) |
| 2020-06-30 | $100.27M | $7.21M | $12.56M | $-120.31M | (m) | 1390.43% | 174.18% | (m) | (m) |
| 2020-03-31 | $91.77M | $36.02M | $12.03M | $-80.47M | (m) | 254.77% | 33.40% | (m) | (m) |
| 2019-12-31 | $89.60M | $36.14M | $11.98M | $-77.10M | (m) | 247.91% | 33.15% | (m) | (m) |
| 2019-09-30 | $81.90M | $35.50M | $10.83M | $-67.51M | (m) | 230.72% | 30.52% | (m) | (m) |
| 2019-06-30 | $72.55M | $34.00M | $9.81M | $-57.31M | (m) | 213.40% | 28.87% | (m) | (m) |
| 2019-03-31 | $60.63M | $5.76M | $8.81M | $-71.41M | (m) | 1053.10% | 153.08% | (m) | (m) |
| 2018-12-31 | $48.61M | $4.82M | $7.61M | $-56.75M | (m) | 1008.11% | 157.80% | (m) | (m) |
| 2018-09-30 | $41.12M | $2.89M | $7.12M | $-50.02M | (m) | 1420.39% | 245.98% | (m) | (m) |
| 2018-06-30 | $33.93M | $2.60M | $6.51M | $-42.08M | (m) | 1304.97% | 250.47% | (m) | (m) |
| 2018-03-31 | $29.44M | $2.10M | $6.00M | $-36.98M | (m) | 1403.87% | 285.95% | (m) | (m) |
| 2017-12-31 | $26.04M | $2.44M | $5.69M | $-32.56M | (m) | 1067.09% | 233.36% | (m) | (m) |
| 2017-09-30 | $23.13M | $2.82M | $5.87M | $-29.27M | (m) | 821.50% | 208.63% | (m) | (m) |
| 2017-06-30 | $21.83M | $2.76M | $5.35M | $-27.65M | (m) | 790.18% | 193.75% | (m) | (m) |
| 2017-03-31 | $19.63M | $2.81M | $4.44M | $-24.55M | (m) | 698.91% | 157.93% | (m) | (m) |
| 2016-12-31 | $15.44M | $1.91M | $3.16M | $-19.99M | (m) | 807.60% | 165.51% | (m) | (m) |
| 2016-09-30 | $11.88M | $1.90M | $1.83M | $-14.91M | (m) | 625.23% | 96.43% | (m) | (m) |
| 2016-06-30 | $9.20M | $1.33M | $1.24M | $-11.83M | (m) | 692.72% | 93.73% | (m) | (m) |
| 2016-03-31 | $7.34M | $1.04M | $1.16M | $-10.21M | $7.89K | 702.33% | 111.25% | -1293.32× | Reported |
| 2015-12-31 | $5.89M | $648.38K | $1.15M | $-8.85M | $2.44K | 908.21% | 177.87% | -3628.56× | Reported |
| 2015-09-30 | $4.64M | (m) | $964.69K | $-7.61M | $2.35K | (m) | (m) | -3241.88× | Reported |
| 2015-06-30 | $3.45M | (m) | $769.57K | $-6.18M | $3.00K | (m) | (m) | -2059.78× | Reported |
| 2015-03-31 | $1.92M | (m) | $489.71K | $-4.08M | $13.84K | (m) | (m) | -294.63× | Reported |
| 2014-12-31 | $1.26M | (m) | $193.12K | $-2.65M | $24.02K | (m) | (m) | -110.20× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $210.67K | (m) | $6.14K | $-557.28K | $45.11K | (m) | (m) | -12.35× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |